Latest vemurafenib Stories
- Differentiated safety profile emerging relative to other MEK/BRAF combination therapies - BOULDER, Colo., June 1, 2015 /PRNewswire/ -- Array BioPharma's wholly-owned MEK inhibitor,
DALLAS, May 19, 2015 /PRNewswire/ -- This melanoma treatment market (therapeutics) report analyzes treatment usage patterns, drug types available and pipeline and market
- Array to receive global rights from Novartis to innovative BRAF inhibitor - BOULDER, Colo., Jan. 23, 2015 /PRNewswire/ -- Array BioPharma Inc.
NEW YORK, Oct.
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass.,
SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K.
- The parings of haberdine; also, any kind of fragments.